ArticleCancer reports (Hoboken, N.J.)2026
PRKD3 Overexpression May Improve Survival and Suppresses Proliferation in Colorectal Cancer.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe study aimed to explore PRKD3 protein expression in colorectal cancer and its clinical implications.
methodsPRKD3 expression was assessed in 189 paired colorectal cancer tissues and their corresponding adjacent non-cancerous counterparts using tissue microarray-based immunohistochemistry. The associations of PRKD3 expression with clinicopathological parameters and patient prognosis were analyzed. PRKD3 mRNA levels were quantified by quantitative real-time polymerase chain reaction (qPCR), and its protein expression in colorectal cancer cell lines was detected by Western blot analysis. To investigate the functional role of PRKD3 in cell proliferation, its expression was knocked down using siRNA transfection, followed by proliferation assays.
resultsImmunohistochemical analysis revealed that PRKD3 protein was predominantly localized in the cytoplasm of both colorectal cancer and adjacent normal epithelial cells (sampled from > 5 cm beyond the tumor margin). The positive expression rate was 51.8% (72/139) in adjacent normal tissues and 68.7% (114/166) in colorectal cancer tissues, showing a statistically significant increase in cancer tissues (p < 0.05). PRKD3 expression was significantly associated with the clinical diagnosis (colon vs. rectal cancer) (p < 0.05). Kaplan-Meier survival analysis demonstrated that patients with high PRKD3 expression had a significantly longer postoperative survival than those with low expression (p < 0.05). Furthermore, cell proliferation assays showed that knockdown of PRKD3 significantly enhanced proliferation ability compared with the control group.
conclusionTaken together, the positive expression of PRKD3 may be associated with better prognosis. These findings suggest that PRKD3 may be involved in the development and progression of colorectal cancer and could represent a potential prognostic biomarker and therapeutic target for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.